Disappointment for Australian company Actinogen Medical (ASX:ACW) with the release of data from its phase 2 clinical trial (XanADu) investigating its investigative therapy Xanamem in patients with mild dementia due to Alzheimer’s disease. …
Latest Video
New Stories
-
Guild rejects hospital call for extended dispensing powers
January 21, 2020 - - Latest News -
PAIG: New structure, executive committee and co-chairs
January 21, 2020 - - Latest News -
Former MA CEO: Transparency is a two-way street
January 21, 2020 - - Latest News -
MTPConnect appoints experienced industry and R&D executive
January 21, 2020 - - Latest News -
One line in a fact sheet that changed PBS decision-making
January 20, 2020 - - Latest News -
How is it considered or taken into account?
January 20, 2020 - - Latest News -
China backs stronger biopharma IP in US trade deal
January 20, 2020 - - Latest News